Pramipexole for Bipolar II Depression: RCT
Archives of General Psychiatry (2004)
Response rate of 60% vs 9% placebo in bipolar II depression, supporting off-label use in treatment-resistant mood disorders.
How it works
Marek's Guided Optimization® Program combines advanced lab testing, a dedicated health coach and medical provider, and a personalized treatment plan, all built around your data.
Resources
The process
1
Start your assessment
Complete your 45-min intake assessment
2
Get your labs drawn
4,000 partnered lab locations nationwide
3
Review with your coach
Screen-by-screen lab review
4
Receive your protocol
Treatment delivered to your door
Why Marek
The only program pairing you with a dedicated health coach and medical provider, built on precision diagnostics, with no subscription required.
Resources
Meet our co-founder
Derek
Co-Founder · MPMD Podcast
"Over time, I found it incredibly difficult to get medical oversight for myself and my family that reflected the latest research, and that was preventative. That's why I started Marek Health."
Excellent on Trustpilot
What we test
Every client's lab panel is hand-selected from 1,000+ available biomarkers, built around their specific goals.
Panel categories
Resources
Treatments
700+ medical provider-prescribed therapies built from your labs. Browse by category or explore the full formulary.
Pramipexole
Oral tablet (0.25mg)Available in all 50 statesMarketing purposes only. Actual medications, if prescribed, are dispensed by a licensed pharmacy.
hormones
PramipexolePramipexole
Non-ergot dopamine agonist with high D2/D3/D4 selectivity. FDA-approved for Parkinson's and RLS. Off-label for treatment-resistant depression, prolactin management, and cognitive/motivational enhancement via D3 mesolimbic effects.
No cardiac valve fibrosis risk (non-ergot)
Strong D3 agonism, antidepressant effects
Effective for RLS
Neuroprotective potential
No commitment · HSA/FSA eligibleNo commitment · HSA/FSA eligible
How it works
Mechanism of action
Direct stimulation of D2, D3, and D4 receptors. D3 activation in the mesolimbic pathway underlies antidepressant and reward-modulating effects. D2 agonism suppresses prolactin.
The baseline panel.
Every Marek client receives this baseline panel before a provider review. Your provider may add additional biomarkers based on your health history, symptoms, and goals, pulling from 1,000+ available markers. See more biomarkers →
Hormone Profile
12 markers
Sex hormones
- Total TestosteroneLC/MS
- Free TestosteroneEquilibrium Dialysis
- Estradiol, Sensitive / UltrasensitiveLC/MS
- Sex Hormone Binding Globulin (SHBG)
- ProgesteroneLC/MSFemale panel
- Prolactin
- Luteinizing Hormone (LH)
- Follicle-Stimulating Hormone (FSH)
- hCG, Total, QuantitativeFemale panel, pre-menopause
Adrenals & neurosteroids
- Cortisol
- DHEA-S
Growth hormone / IGF-1
- Insulin-Like Growth Factor I (IGF-1)
Thyroid Status
3 markers
Thyroid hormones
- Thyroid Stimulating Hormone (TSH)
- Free T4
- Free T3
Heart Health
9 markers
Cardiovascular health
- Total Cholesterol
- HDL Cholesterol
- LDL Cholesterol
- LDL:HDL Ratio
- VLDL Cholesterol
- Triglycerides
- Apolipoprotein-B (ApoB)
- C-Reactive Protein, High Sensitivity (hsCRP)
- Lipoprotein(a) (Lp(a))
Metabolism
3 markers
Insulin sensitivity
- Blood Glucose
- Fasting Insulin
- HbA1c
Organ Function
26 markers
Liver & pancreas
- AST
- ALT
- Bilirubin, Total
- γ-Glutamyl Transferase (GGT)
Kidney function
- BUN
- Creatinine w/ eGFR
Comprehensive Metabolic Panel (CMP)
- Glucose
- Blood Urea Nitrogen (BUN)
- Creatinine
- eGFR
- BUN/Creatinine Ratio
- Sodium
- Potassium
- Chloride
- Carbon Dioxide, Total
- Calcium
- Protein, Total
- Albumin
- Globulin, Total
- Albumin/Globulin (A/G) Ratio
- Alkaline Phosphatase (ALP)
- AST
- ALT
Prostate health
- Prostate-Specific Antigen (PSA)Male panel
- Free PSAMale panel
- % Free PSAMale panel
Nutrient Status
31 markers
Vitamins & minerals
- Vitamin D, 25-OHD (25-Hydroxy)
- Magnesium, RBC
Iron status
- Iron
- Iron Saturation
- TIBC
- UIBC
- Ferritin
Complete Blood Count (CBC)
- White Blood Count (WBC)
- Red Blood Count (RBC)
- Hemoglobin (Hgb)
- Hematocrit (HCT)
- MCV
- MCH
- MCHC
- Red Cell Distribution Width (RDW)
- Platelets
- Neutrophils
- Neutrophils (Absolute)
- Lymphocytes
- Lymphocytes (Absolute)
- Neutrophil/Lymphocyte Ratio
- Monocytes
- Monocytes (Absolute)
- Eosinophils
- Eosinophils (Absolute)
- Basophils
- Basophils (Absolute)
- Immature Cells
- Immature Granulocytes
- Immature Granulocytes (Absolute)
- NRBC, w/ Reflex for Immature Cells
Clinical evidence
The research behind Pramipexole.
Safety profile
Monitoring & safety information.
Commonly reported side effects
- Nausea
- Dizziness
- Somnolence
- Insomnia
- Peripheral edema
Less common but serious risks
- Impulse control disorders (gambling, hypersexuality)
- Sudden sleep attacks
- Psychosis/hallucinations (high doses)
- RLS augmentation with long-term use
Generally not appropriate for
- History of impulse control disorders
- Caution with concurrent antipsychotics
Typical monitoring
- Blood pressure
- Prolactin
- Behavioral assessment (impulse control)
- Sleep symptoms
- Renal function
FAQ
Quick answers.
Non-ergot dopamine agonist with high D2/D3/D4 selectivity. FDA-approved for Parkinson's and RLS. Off-label for treatment-resistant depression, prolactin management, and cognitive/motivational enhancement via D3 mesolimbic effects.
No cardiac valve fibrosis risk (non-ergot). Strong D3 agonism, antidepressant effects. Effective for RLS. Neuroprotective potential.
Common side effects include: nausea, dizziness, somnolence, insomnia, peripheral edema. Most side effects are dose-dependent and may resolve with continued use or dose adjustment.
Non-ergot dopamine agonist with high D2/D3/D4 selectivity. FDA-approved for Parkinson's and RLS. Off-label for treatment-resistant depression, prolactin management, and cognitive/motivational enhancement via D3 mesolimbic effects.
Treatments are dependent on licensed clinical prescription. Client costs vary based on individual labs and panel in treatments and services.